Navigation Links
Johnson & Johnson Completes Tender Offer for Omrix Biopharmaceuticals, Inc.
Date:12/27/2008

NEW BRUNSWICK, N.J., Dec. 27 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ) today announced that stockholders of Omrix Biopharmaceuticals, Inc. (Nasdaq: OMRI) ("Omrix") tendered approximately 16,749,152 shares of Omrix common stock, including approximately 1,293,924 shares subject to guaranteed delivery procedures, representing approximately 97.8% of Omrix's outstanding common stock. According to the terms of Johnson & Johnson's tender offer, shares that were validly tendered and not withdrawn have been accepted for payment. The tender offer expired at 12:00 midnight (Eastern time) on Dec. 26, 2008, and was not extended.

Johnson & Johnson intends to complete the acquisition of Omrix through what is known as a "short-form merger," that is, without a vote or meeting of Omrix's remaining stockholders. Each of the remaining shares of Omrix common stock (other than shares owned by stockholders of Omrix who properly exercised their appraisal rights under Delaware law) will be converted into the right to receive $25.00 per share, less any required withholding taxes, in cash and without interest, which is the same amount per share that was paid in the tender offer. The merger is expected to occur as soon as practicable. Following the merger, Omrix is expected to operate as a stand-alone entity reporting through ETHICON, Inc., a Johnson & Johnson company and Omrix's common stock will no longer list on NASDAQ.

About Johnson & Johnson

Caring for the world, one person at a time...inspires and unites the people of Johnson & Johnson. We embrace research and science -- bringing innovative ideas, products and services to advance the health and well-being of people. Our 119,400 employees at more than 250 Johnson & Johnson companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

Additional Information

This press release is neither an offer to purchase nor a solicitation of an offer to sell shares of Omrix.


'/>"/>
SOURCE Johnson & Johnson
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Johnson & Johnson to Participate in Bear Stearns 20th Annual Healthcare Conference
2. Draxis Health selected by Johnson and Johnson Consumer Companies, Inc. for major contract manufacturing relationship
3. Johnson & Johnson Campaign for Nursings Future Joins With AACN to Offer New Minority Nurse Faculty Scholars Program
4. Trust for Americas Health Receives $7.6 Million Grant from the Robert Wood Johnson Foundation to Advance the Quality and Impact of the Public Health System
5. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
6. Johnson & Johnson Tops Annual Pharmaceutical Company Rankings in a New Report From Industry-Leading Publication Scrip
7. Independence Technology, A Johnson & Johnson Company, Renews Its Contract With Creative Technology Services
8. Johnson & Johnson Launches Global Diabetes Institute to Provide State-of-The- Art Education, Training to Health Professionals
9. Robert Wood Johnson Foundation Announces $15.6 Million Grant to Apply Power of the Archimedes Model to Critical Health Care Decisions
10. UAN Mourns Passing of President Cheryl L. Johnson, RN
11. Johnson & Johnson Pharmaceutical Research & Development Submits New Drug Application for Paliperidone Palmitate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... May 03, 2016 , ... Each year, about 800,000 people suffer from ... the United States and account for one death every four minutes. Many people ... disabled. HCR ManorCare is launching a video series called “Your Brain,” in conjunction with ...
(Date:5/3/2016)... Indianapolis, IN (PRWEB) , ... May 03, 2016 ... ... employee benefits advisory organization, announces Benefits Alliance Insurance Services as the latest addition ... powerhouse Southern California-based Firm comprised of Partners Wayne Blasman, David Styles, and Paul ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... technology (IT) solutions and digital consulting services to the federal government, has been ... Indefinite Delivery / Indefinite Quantity (ID/IQ) contract in support of the U.S. Army ...
(Date:5/3/2016)... Jersey City, NJ (PRWEB) , ... May 03, ... ... today announced the general availability of the latest release of DocAve 6 ... this release, AvePoint helps organizations migrate to SharePoint 2016 and take advantage of ...
(Date:5/3/2016)... ... May 03, 2016 , ... Finding the right way to address a patient’s condition before ... is now getting on board. , “You do the right thing, at the right time, ... goes down, not up,” said Leonard M. Fromer, MD, FAAFP, from Group Practice Forum. “Even ...
Breaking Medicine News(10 mins):
(Date:5/2/2016)... , May 2, 2016  Celsion Corporation (NASDAQ: ... today announced data from the first cohort of ... trial (the OVATION Study) combining GEN-1, the Company,s ... the treatment of newly-diagnosed patients with advanced ovarian ... interval debulking surgery.  In the first three patients ...
(Date:4/29/2016)... 29, 2016 ... Sanofi, leader mondial et ... résultats pour le premier trimestre 2016. ... Contamine, commente les résultats du premier ... pour le reste de l,année. ...
(Date:4/28/2016)... , April 28, 2016 ... "Global Plastic Surgery Products Market 2016-2020" report ... ) , The global plastic surgery ... of 9.47% during the period 2016-2020. , ,The growing ... leading to the growth of the market. Lasers are ...
Breaking Medicine Technology: